EQT Life Sciences, a part of Swedish private equity company EQT AB (STO: EQT), announced on Monday that it has exited Vivasure Medical Limited, an Ireland-based developer of percutaneous vessel closure technology, through a sale to US medical technology group Haemonetics Corporation (NYSE: HAE).

Vivasure develops the PerQseal Elite system, which uses a bioabsorbable patch to seal large arterial or venous access sites from within, providing a sutureless and fully absorbable solution for structural heart and endovascular procedures. In 2025, the company submitted a Premarket Approval application to the US Food and Drug Administration for PerQseal Elite and received CE Mark approval in Europe for arterial and venous use.

EQT Life Sciences, formerly LSP, first invested in Vivasure in 2016 via the LSP Health Economics Fund, leading its Series C round. The transaction includes an upfront cash payment of EUR100m and up to EUR85m in contingent consideration linked to sales growth and other milestones, and the LSP Health Economics Fund will receive a portion of the proceeds reflecting its minority shareholding.

Haemonetics Corporation said the acquisition expands its range of closure devices and strengthens its position in the large-bore closure market for structural heart and endovascular procedures.